💊Opdivo (nivolumab) Demonstrates Superior Three-Year Survival Benefit for Patients with Previously Treated Advanced Renal Cell Carcinoma (RCC)

By Cancer, FDA

💊Opdivo (nivolumab) Demonstrates Superior Three-Year Survival Benefit for Patients with Previously Treated Advanced Renal Cell Carcinoma (RCC) .

PRINCETON, N.J.–(BUSINESS WIRE)–Bristol-Myers Squibb Company (NYSE:BMY) announced today a three-year overall survival (OS) update from its phase 3 CheckMate -025 study, evaluating patients treated with Opdivo (nivolumab) versus everolimus in previously treated advanced renal cell carcinoma (RCC). These data are the first of any anti-PD-1 agent to demonstrate durable survival at three years in previously treated RCC.
No new safety signals were identified and the data showed a safety profile consistent with two-year results. BMS Newsroom

https://news.bms.com/press-release/corporatefinancial-news/opdivo-nivolumab-demonstrates-superior-three-year-survival-ben

More from tokioX :

  1. FDA ：Opdivo® as the First New Medication for Certain Patients with Previously Treated Small Cell Lung Cancer
  2. FDA: Eisai ‘s “Rembima” approved as a hepatocellular cancer drug
  3. Opivibo, the first cancer immunotherapy drug in China, approved by the Chinese National Drug Administration and Supervision Agency for indications of treatment non-small cell lung cancer with history
  4. 💊FDA PHARMA today
  5. 💊FDA PHARMA today
  6. 💊Pharma – News Releases
  7. 💊Bristol-Myers Squibb Company, Opivo® (generic name: niborumab), approved as Fda as a treatment for hepatocellular cancer patients with treatment history with sorafenib  20170927